The RTN4IP1 antibody targets the reticulon 4-interacting protein 1 (RTN4IP1), a mitochondrial enzyme implicated in neuronal development and metabolic regulation. RTN4IP1. also known as neuroendocrine regulatory protein 2 (NERP2), interacts with reticulon 4 (RTN4/NOGO) to modulate mitochondrial function, oxidative phosphorylation, and neuroaxonal growth. It belongs to the NADH dehydrogenase (ubiquinone) complex and plays a role in maintaining mitochondrial integrity, energy production, and reactive oxygen species (ROS) homeostasis. Dysregulation of RTN4IP1 is associated with neurological disorders, including optic atrophy, epilepsy, and neurodevelopmental defects.
Antibodies against RTN4IP1 are primarily used in research to investigate its expression, localization, and mechanistic roles in cellular and animal models. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding studies on mitochondrial dynamics, neuronal connectivity, and disease pathology. Recent studies highlight RTN4IP1's involvement in zebrafish visual system development and mammalian brain function, emphasizing its conservation across species. Researchers also explore its potential as a biomarker or therapeutic target for mitochondrial encephalopathies. Commercial RTN4IP1 antibodies are typically validated for specificity in human, mouse, or rat tissues, supporting translational research in neurodegeneration and metabolic syndromes.